Canada Markets close in 3 hrs 12 mins

Mind Medicine (MindMed) Inc. (MMDCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.06500.0000 (0.00%)
As of 09:46AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0650
Open0.0650
BidN/A x N/A
AskN/A x N/A
Day's Range0.0650 - 0.0650
52 Week Range0.0650 - 0.0650
Volume551
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    MindMed Appoints Schond L. Greenway as Chief Financial Officer

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector.

  • CNW Group

    MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

    Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.

  • CNW Group

    MindMed Announces At-The-Market Offering

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was declared effective by the U.S. Securities and Exchange Commission, which includes a prospectus for an at-the-market equity offering under which the Company may offer and sell its Subordinate Voting Shares or common shares re-designated f